Table 1—

Patient demographics

CharacteristicInfectedUninfected
Subjects1733
Age yrs50±1350±10
Sex M:F12:516:17
Pre-transplant diagnosis
 IPF7 (41)9 (27)
 COPD4 (24)10 (30)
 AAT1 (8)3 (9)
 CF2 (12)4 (12)
 PPH2 (12)3 (9)
 Other#1 (6)4 (12)
Immunosuppresssion
 Cyclosporine16 (94)29 (88)
 Tacrolimus1(6)4 (12)
 Azathioprine12 (71)27 (81)
 Mycophenylate3 (18)5 (15)
Time post-transplant+1335 (61–3104)786 (19–2651)
Previous BO or BOS2 (12)5 (15)
Single lung transplant12 (71)24 (73)
Double lung transplant4 (24)8 (24)
Heart–lung transplant1 (4)1 (3)
  • Data are presented as n, mean±sd, n (%) or median (range). M: male; F: female; IPF: idiopathic pulmonary fibrosis; COPD: chronic obstructive pulmonary disease; AAT: α1-antitrypsin deficiency; CF: cystic fibrosis; PPH: primary pulmonary hypertension; BO: bronchiolitis obliterans; BOS: bronchiolitis obliterans syndrome. #: sarcoidosis, lymphangioleiomyomatosis, Eisenmenger's syndrome and post-adult respiratory distress syndrome fibrosis; : one patient in both groups was enrolled in a trial comparing azathioprine and everolimus, all patients were receiving prednisone; +: p = 0.04 (Mann–Whitney U-test), all other comparisons between infected and uninfected patients were not significant.